DNA-PK/HDAC6-IN-2
DNA-PK/HDAC6-IN-2 is an orally active and selective dual-target inhibitor of DNA-PK and HDAC6, with an IC50 of 34.22 nM for DNA-PK and an IC50 of 241.2 nM for HDAC6. DNA-PK/HDAC6-IN-2 upregulates Ac‑α‑tubulin, inhibits p‑DNA‑PK, and increases γ‑H2AX. DNA-PK/HDAC6-IN-2 exhibits antiproliferative activity against multiple solid tumor cell lines, induces apoptosis and cell cycle arrest, and inhibits migration and invasion. DNA-PK/HDAC6-IN-2 has in vivo antitumor efficacy in melanoma and breast cancer models and enhances the efficacy of Doxorubicin (HY-15142A). DNA-PK/HDAC6-IN-2 can be used for research on various cancers such as melanoma, breast cancer, and colorectal cancer.
For research use only. We do not sell to patients.
- CAS No.: 3107156-58-8
- Formula: C23H30N6O5
- Molecular Weight:470.52
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
HDAC6 241.2 nM (IC50) |
α-Tubulin |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | IC50 |
24.96 μM
|
Antiproliferative activity against mouse 4T1 cells assessed as IC50.
Antiproliferative activity against mouse 4T1 cells assessed as IC50.
|
42743643 |
| SK-OV-3 | IC50 |
18.42 μM
|
Antiproliferative activity against human SK-OV-3 cells assessed as IC50.
Antiproliferative activity against human SK-OV-3 cells assessed as IC50.
|
42743643 |
| HCT-116 | IC50 |
22.29 μM
|
Antiproliferative activity against human HCT-116 cells assessed as IC50.
Antiproliferative activity against human HCT-116 cells assessed as IC50.
|
42743643 |
| B16-F10 | IC50 |
19.18 μM
|
Antiproliferative activity against mouse B16-F10 cells assessed as IC50.
Antiproliferative activity against mouse B16-F10 cells assessed as IC50.
|
42743643 |
In Vitro
DNA-PK/HDAC6-IN-2 (DH-6) exhibited an IC50 of 34.22 nM against DNA-PK and an IC50 of 241.2 nM against HDAC6 in cell-free enzymatic assays; it displayed antiproliferative activity in 4T1, SK-OV-3, HCT-116, and B16-F10 cells with an average IC50 of 21.21 μM[1].
DNA-PK/HDAC6-IN-2 (10-20 μM; 0-24 h) inhibits B16-F10 migration and invasion, and upregulates E-cadherin while downregulating N-cadherin in B16-F10 cells[1].
DNA-PK/HDAC6-IN-2 (5-20 μM; 24 h) induces apoptosis and G2/M phase arrest in B16-F10 cells, accompanied by increases in cleaved caspase-3, cleaved PARP, and P21[1].
DNA-PK/HDAC6-IN-2 (5-20 μM; 24 h) enhances Doxorubicin (HY-15142A)-induced DNA damage in B16-F10 cells by increasing γ-H2AX expression and comet tailing[1].
DNA-PK/HDAC6-IN-2 (1.25-20 μM; 24 h) upregulated Ac-α-tubulin in HCT-116 and B16-F10 cells without affecting Ac-H3, total H3, or total α-tubulin, and reduced PD-L1 in B16-F10 cells[1].
DNA-PK/HDAC6-IN-2 (20 μM; 30 min-16 h) in combination with Doxorubicin (HY-15142A) increases γ-H2AX and decreases p-DNA-PK in B16-F10 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:B16-F10 cells
-
Concentration:10, 20 μM
20 μM (wound healing assay) -
Incubation Time:24 h
0, 12, 24 h (wound healing assay) -
Result:Inhibited B16-F10 migration and invasion, and upregulates E-cadherin while downregulating N-cadherin in B16-F10 cells.
-
Cell Line:B16-F10 cells
-
Concentration:20 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in B16-F10 cells in a concentration-dependent manner: 32.0% apoptotic cells at 5 μM and 48.7% at 20 μM.
Induced significant G2/M phase arrest.
Upregulated cleaved caspase-3, cleaved PARP, and P21 in a concentration-dependent manner.
-
Cell Line:HCT-116 and B16-F10 cells
-
Concentration:1.25, 2.5, 5.0, 10 μM (Western blot for Ac-α-tubulin/Ac-H3/H3/α-tubulin in HCT-116 and B16-F10)
2.5, 5, 10, 20 μM (Western blot for Ac-α-tubulin and PD-L1 in B16-F10) -
Incubation Time:24 h
-
Result:Upregulated Ac‑α‑tubulin in HCT‑116 and B16‑F10 cells while exerting no obvious influence on Ac‑H3, total H3, or total α‑tubulin.
Produced concentration‑dependent Ac‑α‑tubulin expression and reduced PD‑L1 expression similarly to ACY‑1215 in B16‑F10 cells.
-
Cell Line:B16-F10 cells
-
Concentration:20 μM; Doxorubicin (HY-15142A) 100 nM
-
Incubation Time:30 min, 2, 4, 8, 16 h
-
Result:Combined with Doxorubicin elevates γ-H2AX and reduces p-DNA-PK in B16-F10 cells.
Parmacokinetics
In Vivo
DNA-PK/HDAC6-IN-2 (25 mg/kg; i.p.; QD) enhanced the efficacy of Doxorubicin (HY-15142A) in the 4T1-Luc breast cancer model, achieving a TGI of 73.6% in combination therapy[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 4 weeks old, 3 × 105 B16-F10 cells)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; daily; for two weeks
-
Result:Suppressed tumor volume with a tumor growth inhibition rate (TGI) of 78.2%.
In melanoma tumor tissues, DH-6 increased intratumoral Ac-α-tubulin and γ-H2AX levels and reduced p-DNA-PK levels, with no obvious influence on total DNA-PK or Ac-H3 expression.
-
Animal Model:Balb/c (female, 6 weeks old, 100 μL of
4T1-Luc cells into the armpit)[1] -
Dosage:25 mg/kg (DH-6); 2.5 mg/kg (Doxorubicin)
-
Administration:DH-6: i.p.; QD; 14 days; Doxorubicin: i.v.; days 1 and 8
-
Result:Reduced tumor volume relative to doxorubicin monotherapy upon combination of DH‑6 plus doxorubicin, achieving a TGI of 73.6%.
Observed a marked decrease in tumor weight.
Confirmed enhanced doxorubicin therapeutic efficacy by fluorescence imaging of mouse tumors.
Chemical Information
-
CAS No. 3107156-58-8
-
Molecular Weight 470.52
-
Formula C23H30N6O5
-
SMILES
CC1=C(C=C(C=C1)OCCCCC(NO)=O)NC2=NC=C3C(N(C(N3C)=O)C4CCOCC4)=N2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)